Referencia número: HY-13771

Ursodeoxycholic acid

(Synonyms: Ursodeoxycholate; Ursodiol; UDCA)

30 Cited Publications

Revisión del cliente

Based on 30 publication(s) in Google Scholar

Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.94%
No. CAS: 128-13-2
Fòrmula: C₂₄H₄₀O₄
Peso molecular:392.57

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Ursodeoxycholic acid Chemical Structure

No. CAS: 128-13-2

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Ensayo clínico
Chemical Information
Publications (30)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target^[3]^[4]

Human Endogenous Metabolite

Ver todos los productos específicos de isoformas Endogenous Metabolite :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>200 μM Compound: UDCA	Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
CHO	EC₅₀	36.4 μM Compound: 9, UDCA	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]
COS-1	EC₅₀	>50 μM Compound: 9, UDCA	Agonist activity at human FXR expressed in COS1 cells by luciferase assay Agonist activity at human FXR expressed in COS1 cells by luciferase assay	[PMID: 18307294]
GBM	IC₅₀	>50 μM Compound: 1b, UDCA, ursodeoxycholic acid	Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay	[PMID: 20381215]
HCT-116	IC₅₀	>200 μM Compound: UDCA	Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
HCT-116	IC₅₀	>50 μM Compound: 1b, UDCA, ursodeoxycholic acid	Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay	[PMID: 20381215]
HEK293	EC₅₀	2.39 μM Compound: 3, UDCA	Agonist activity at human GPBAR1 expressed in HEK293 cells assessed as increase in intracellular cAMP level after 30 mins by cAMP-Glo assay Agonist activity at human GPBAR1 expressed in HEK293 cells assessed as increase in intracellular cAMP level after 30 mins by cAMP-Glo assay	[PMID: 25735208]
HEK-293T	EC₅₀	>150 μM Compound: UDCA	Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay	[PMID: 26774929]
HEK-293T	IC₅₀	>50 μM Compound: UDCA	Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay	[PMID: 26774929]
HeLa	IC₅₀	3.6 μM Compound: Ursodeoxycholate	TP_TRANSPORTER: inhibition of Taurocholate uptake in NTCP-expressing HeLa cells TP_TRANSPORTER: inhibition of Taurocholate uptake in NTCP-expressing HeLa cells	[PMID: 10565843]
HET-1A	CC₅₀	1313 μM Compound: 7, UDCA	Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 20713311]
HT-29	IC₅₀	>200 μM Compound: UDCA	Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
Huh-7	IC₅₀	>200 μM Compound: UDCA	Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
KMS-11	IC₅₀	>50 μM Compound: 1b, UDCA, ursodeoxycholic acid	Cytotoxicity against human KMS11 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human KMS11 cells after 24 hrs by neutral red uptake assay	[PMID: 20381215]
LoVo	IC₅₀	>200 μM Compound: UDCA	Anticancer activity against human LoVo cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human LoVo cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
MGC-803	IC₅₀	>200 μM Compound: UDCA	Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
RKO	IC₅₀	>200 μM Compound: UDCA	Anticancer activity against human RKO cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human RKO cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
SK-HEP1	IC₅₀	>200 μM Compound: UDCA	Anticancer activity against human SK-HEP1 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human SK-HEP1 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]
SW480	IC₅₀	>200 μM Compound: UDCA	Anticancer activity against human SW480 cells assessed as inhibition of cell proliferation by MTT assay Anticancer activity against human SW480 cells assessed as inhibition of cell proliferation by MTT assay	[PMID: 36439975]

In Vitro

Ursodeoxycholic acid (10 μM; 24 h) reduces ACE2 and SHP levels in primary airway and intestinal organoids, and reduces SARS-CoV-2 infection in multiple cell types via FXR-mediated ACE2 regulation^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ursodeoxycholic acid (50, 150, and 450 mg/kg; p.o.; daily for 21 days) results in weight loss in C57BL/6J wildtype mice^[1].
Ursodeoxycholic acid (1% w/w or 416 mg/kg; oral; 7 days) reduces ACE2 expression in mice and hamsters^[4].
Ursodeoxycholic acid (416 mg/kg; oral; 7 days) reduces SARS-CoV-2 infection in hamsters^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

5 week old C57BL/6J WT mice (male and female)^[1]
Dosage:

50, 150, and 450 mg/kg dissolved in corn oil
Administration:

Oral gavage; daily for 21 days
Result:

Mice in the 50 and 450 mg/kg groups sustained significant weight loss within a week. At 50 mg/kg, this weight loss persisted over the course of the experiment. At 450 mg/kg, initially weight loss was noted during the first and third week of ursodiol administration. At 150 mg/kg, it did not have significantly different weights compared to the untreated mice.

Animal Model:

FVB/N mice and Syrian Golden Hamsters^[4]
Dosage:

1% w/w for mice, 416 mg/kg for hamsters
Administration:

In chow or oral gavage, 7 days
Result:

Reduced ACE2 expression.

Animal Model:

Syrian Golden Hamsters, SARS-CoV-2 infection model^[4]
Dosage:

416 mg/kg
Administration:

Oral gavage, 7 days
Result:

Prevented transmission of SARS-CoV-2 in n=6 out of 9 sentinel animals (33% infected vs. 67% uninfected).

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 128-13-2
Appearance Solid
Peso molecular 392.57
Fòrmula C₂₄H₄₀O₄
Color White to off-white
SMILES

C[C@H](CCC(O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C
Synonyms

Ursodeoxycholate; Ursodiol; UDCA
Structure Classification
- Steroids
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (30)

All RT-PCROthersWBIFHistological Imaging/Staining

Sort by:

Journal Impact Factor

Nature

Lithocholic acid phenocopies anti-ageing effects of calorie restriction. [Abstract]

2025 Jul;643(8070):192-200. PMID: 39695227
Cell Host Microbe

A gut microbiota-bile acid axis promotes intestinal homeostasis upon aspirin-mediated damage. [Abstract]

2024 Feb 14;32(2):191-208.e9. PMID: 38237593

Ursodeoxycholic acid purchased from MedChemExpress. Usage Cited in: Cell Host Microbe. 2024 Feb 14;32(2):191-208.e9. [Abstract]

H&E-stained demonstrated Ursodeoxycholic acid (UDCA) (50 mg/kg/day, gavage, 2 weeks) and 7-keto-LCA protected against aspirin-induced intestinal epithelial damage.
Nat Commun

Cholecystectomy-related gut microbiota dysbiosis exacerbates colorectal tumorigenesis. [Abstract]

2025 Aug 16;16(1):7638. PMID: 40819131

Ursodeoxycholic acid purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 16;16(1):7638. [Abstract]

Mice were gavaged with B. breve or R. gnavus and then treated with BSH inhibitor riboflavin or 7β-HSDH inhibitor Ursodeoxycholic acid (UDCA) (50 mg/kg, p.o.) H&E staining showed normal, dysplastic mucosae and carcinoma in the colon tissues.
Nat Commun

Reduced hepatic bradykinin degradation accounts for cold-induced BAT thermogenesis and WAT browning in male mice. [Abstract]

2023 May 2;14(1):2523. PMID: 37130842

Ursodeoxycholic acid purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 May 2;14(1):2523. [Abstract]

Ursodeoxycholic acid (UDCA) (0.1 mM, 6 h) blocked OA-decreased PREP activity and -increased BK content.
Adv Sci (Weinh)

Medicago Sativa L. Saponin-Driven Lactobacillus Intestinalis Restores Intestinal Stemness in Naturally Aged Mice via the Bile Acid-FXR-Wnt Signaling Axis. [Abstract]

2025 Oct 27:e15370. PMID: 41144719

Ursodeoxycholic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 27:e15370. [Abstract]

RT‐PCR analysis showed that Ursodeoxycholic acid (UDCA) (20 μM. 24 h) supplementation significantly increased the mRNA levels of critical markers of ISCs.

Ursodeoxycholic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 27:e15370. [Abstract]

Protein immunoblotting analysis showed that Ursodeoxycholic acid (UDCA) (20 μM, 24 h) supplementation reduced the protein expression of the bile acids receptor FXR.

Ursodeoxycholic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 27:e15370. [Abstract]

Ursodeoxycholic acid (UDCA) (20 μM, 7 days) treatment increased the protein levels of active β‐catenin in organoid cultures by immunofluorescence images.
Adv Sci (Weinh)

Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis. [Abstract]

2025 Mar;12(12):e2411719. PMID: 39899681

Ursodeoxycholic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(12):e2411719. [Abstract]

The mRNA levels of ALDOB in Huh7 or HCCLM3 cells treated with various bile acids (100 μM, 24 h). All data are presented as mean ± SD. Data were analyzed by one-way ANOVA with Bonferroni multiple-comparison correction. CA, cholic acid; TCA, taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; LCA, lithocholic acid; TLCA, taurolithocholic acid; GLCA, glycolithocholic acid; DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; GDCA, glycodeoxycholic acid; UDCA, ursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; GUDCA, glycoursodeoxycholic acid.
Phytomedicine

Yinzhihuang formula modulates the microbe‒gut‒liver axis and bile acid excretion to attenuate cholestatic liver injury. [Abstract]

2025 Apr:139:156495. PMID: 39978276
Phytomedicine

Investigating the potential mechanism and therapeutic effects of SLXG for cholesterol gallstone treatment. [Abstract]

2024 Sep:132:155886. PMID: 39059092
J Transl Med

Conjugated bile acids alleviate acute pancreatitis through inhibition of TGR5 and NLRP3 mediated inflammation. [Abstract]

2024 Dec 20;22(1):1124. PMID: 39707318
Food Res Int

2026 Feb 17.
Mater Today Adv

2026 May 6;30:100799.
Free Radic Biol Med

Ursodeoxycholic acid protects against cisplatin-induced acute kidney injury and mitochondrial dysfunction through acting on ALDH1L2. [Abstract]

2020 May 20:152:821-837. PMID: 32004633
Cell Prolif

Suppression of the gut microbiota-bile acid-FGF19 axis in patients with atrial fibrillation. [Abstract]

2023 Nov;56(11):e13488. PMID: 37186335
J Ethnopharmacol

Eupalinolide B ameliorates liver fibrosis by targeting PKCα to suppress the AKT/mTOR axis in hepatic stellate cells. [Abstract]

2026 May 23:363:121421. PMID: 41759558
JCI Insight

FXR shapes an immunosuppressive microenvironment in PD-L1lo/- non-small cell lung cancer by upregulating HVEM. [Abstract]

2025 Sep 23;10(18):e190716. PMID: 40985894
Cells

Cartilaginous Metabolomics Reveals the Biochemical-Niche Fate Control of Bone Marrow-Derived Stem Cells. [Abstract]

2022 Sep 21;11(19):2951. PMID: 36230915
Commun Biol

Ursodeoxycholic acid alleviates aortic aneurysm and dissection through the intestinal farnesoid X receptor/ceramide synthase 2 axis. [Abstract]

2025 Jul 5;8(1):1009. PMID: 40617906
Eur J Pharmacol

Integrative Mendelian randomization and experimental validation unveil novel druggable targets in primary biliary cholangitis. [Abstract]

2026 Apr 10:1020:178775. PMID: 41819524
Eur J Pharmacol

Intestinal-restricted farnesoid X receptor agonist Fex3 alleviates cholestatic liver injury via FGF15-CYP7A1 axis. [Abstract]

2026 Apr 29:178910. PMID: 42067015
Int Immunopharmacol

Pedunculoside ameliorates liver fibrosis by targeting c-Jun to inhibit hepatic stellate cell activation. [Abstract]

2026 Jun 15:179:116602. PMID: 41936306
Int J Mol Sci

Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data. [Abstract]

2024 Jan 11;25(2):919. PMID: 38255993
Biochim Biophys Acta Mol Basis Dis

Bile acids mediate fructose-associated liver tumour growth in mice. [Abstract]

2024 Mar;1870(3):167029. PMID: 38325224
Aquaculture

2024 Nov 15.
Microbiol Spectr

Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon. [Abstract]

2026 Jun 2;14(6):e0363325. PMID: 42112801
Vet Microbiol

Ursodeoxycholic acid against TGEV infection via the JAK-STAT1 signaling pathway. [Abstract]

2026 May:316:110973. PMID: 41806593
Neurosci Lett

Ursodeoxycholic acid protects dopaminergic neurons from oxidative stress via regulating mitochondrial function, autophagy, and apoptosis in MPTP/MPP+-induced Parkinson's disease. [Abstract]

2021 Jan 10:741:135493. PMID: 33181233
Lett Drug Des Discov

2025 Nov 26.
Clin Neuropharmacol

Protective Effects of Ursodeoxycholic Acid Against Oxidative Stress and Neuroinflammation Through Mitogen-Activated Protein Kinases Pathway in MPTP-Induced Parkinson Disease. [Abstract]

2022 Nov-Dec;45(6):168-174. PMID: 36383915
Res Sq

2025 Nov 17.
Research Square Preprint

2021 Aug.

Solvente y solubilidad

In Vitro:

DMSO : ≥ 100 mg/mL (254.73 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5473 mL

12.7366 mL

25.4732 mL

5 mM

0.5095 mL

2.5473 mL

5.0946 mL

10 mM

0.2547 mL

1.2737 mL

2.5473 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (280 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Winston JA, et al. Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. PLoS One. 2021;16(2):e0246161. Published 2021 Feb 18. [Content Brief]

[2]. Jackson H, et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology. 2007 Oct;46(4):1131-7. [Content Brief]

[3]. Kumar D, et al. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol. 2001 Jan;16(1):3-14. [Content Brief]

[4]. Brevini T, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2022 Dec 5. [Content Brief]

[5]. Biao Nie, et al. Specific Bile Acids Inhibit Hepatic Fatty Acid Uptake in Mice. Hepatology. 2012 Oct;56(4):1300-10. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5473 mL	12.7366 mL	25.4732 mL	63.6829 mL
	5 mM	0.5095 mL	2.5473 mL	5.0946 mL	12.7366 mL
	10 mM	0.2547 mL	1.2737 mL	2.5473 mL	6.3683 mL
	15 mM	0.1698 mL	0.8491 mL	1.6982 mL	4.2455 mL
	20 mM	0.1274 mL	0.6368 mL	1.2737 mL	3.1841 mL
	25 mM	0.1019 mL	0.5095 mL	1.0189 mL	2.5473 mL
	30 mM	0.0849 mL	0.4246 mL	0.8491 mL	2.1228 mL
	40 mM	0.0637 mL	0.3184 mL	0.6368 mL	1.5921 mL
	50 mM	0.0509 mL	0.2547 mL	0.5095 mL	1.2737 mL
	60 mM	0.0425 mL	0.2123 mL	0.4246 mL	1.0614 mL
	80 mM	0.0318 mL	0.1592 mL	0.3184 mL	0.7960 mL
	100 mM	0.0255 mL	0.1274 mL	0.2547 mL	0.6368 mL

Keywords

Ursodeoxycholic acid

30 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Ursodeoxycholic acid

Chenodeoxycholic Acid

Deoxycholic acid

Lithocholic acid

Cholic acid

Taurochenodeoxycholic acid

Tauroursodeoxycholate

Hyodeoxycholic acid

Glycocholic acid

Glycochenodeoxycholic acid

Serotonin